BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/20/2017 5:58:00 PM | Browse: 1031 | Download: 1890
 |
Received |
|
2016-10-14 09:53 |
 |
Peer-Review Started |
|
2016-10-14 21:49 |
 |
To Make the First Decision |
|
2016-12-01 15:41 |
 |
Return for Revision |
|
2016-12-02 17:16 |
 |
Revised |
|
2016-12-16 17:58 |
 |
Second Decision |
|
2016-12-29 10:49 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2017-01-04 16:30 |
 |
Articles in Press |
|
2017-01-04 16:30 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
2017-01-17 13:36 |
 |
Typeset the Manuscript |
|
2017-02-10 15:47 |
 |
Publish the Manuscript Online |
|
2017-02-20 17:58 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Chemistry, Medicinal |
Manuscript Type |
Basic Study |
Article Title |
Investigation of mitigating effect of colon-specific prodrugs of boswellic acid on 2,4,6-trinitrobenzene sulfonic acid-induced colitis in Wistar rats: Design, kinetics and biological evaluation
|
Manuscript Source |
Invited Manuscript |
All Author List |
Ajinkya Sarkate and Suneela S Dhaneshwar |
Funding Agency and Grant Number |
|
Corresponding Author |
Suneela S Dhaneshwar, PhD, Professor, Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune, Maharashtra 411038,
India. suneeladhaneshwar@rediffmail.com
|
Key Words |
Inflammatory bowel disease; Boswellic acid; Complementary and alternative medicine; Colon-targeting; Mutual prodrugs; Amino acids; TNBS-induced colitis |
Core Tip |
Boswellic acids (BAs) are traditionally used in the treatment of inflammatory diseases and are effective in the treatment of inflammatory bowel disease (IBD) in particular, but they undergo extensive metabolism that results in low oral bioavailability. Colon-targeted delivery of BA was achieved by designing prodrugs that deliver BA site-specifically. The synthesized prodrugs were designed by semi-synthetic approach, wherein β-boswellic acid (BBA) was derivatized into a bioreversible delivery system by incorporation of amino acids as promoities for targeted delivery to inflamed colon in IBD. Prodrug of BBA with L-tryptophan (BT) was 1.7-times more effective than sulfasalazine (SLZ) in 2,4,6-trinitrobenzene sulfonic acid-induced colitis in Wistar rats. In vivo behavior of prodrug BT was very interesting and similar to SLZ, which is known to treat local inflammation in IBD as well as in rheumatoid arthritis (RA). The outcome of this study strongly suggests that these prodrugs might have dual applicability to IBD and chronotherapy of RA.
|
Publish Date |
2017-02-20 17:58 |
Citation |
Sarkate A, Dhaneshwar SS. Investigation of mitigating effect of colon-specific prodrugs of boswellic acid on 2,4,6-trinitrobenzene sulfonic acid-induced colitis in Wistar rats: Design, kinetics and biological evaluation. World J Gastroenterol 2017; 23(7): 1147-1162 |
URL |
http://www.wjgnet.com/1007-9327/full/v23/i7/1147.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v23.i7.1147 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345